Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glomerular Filtration Rate
|
1033 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.700 | 1.000 | 1 | 2019 | 2019 | |||||
Breast Carcinoma
|
2793 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.100 | 0.895 | 38 | 2000 | 2018 | |||||
Malignant neoplasm of breast
|
3417 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.100 | 0.895 | 38 | 2000 | 2018 | |||||
Neoplasms
|
1644 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.050 | 0.600 | 5 | 2007 | 2013 | |||||
Malignant Neoplasms
|
1641 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.030 | 0.667 | 3 | 2010 | 2019 | |||||
Primary malignant neoplasm
|
1374 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.030 | 0.667 | 3 | 2010 | 2019 | |||||
Carcinoma, Ovarian Epithelial
|
327 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.020 | 0.500 | 2 | 2016 | 2018 | |||||
Colorectal Carcinoma
|
1962 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.020 | 0.500 | 2 | 2002 | 2019 | |||||
HER2-positive carcinoma of breast
|
26 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.020 | 1.000 | 2 | 2014 | 2015 | |||||
Malignant neoplasm of colon and/or rectum
|
502 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.020 | 0.500 | 2 | 2002 | 2019 | |||||
Malignant neoplasm of ovary
|
315 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.020 | 0.500 | 2 | 2016 | 2018 | |||||
ovarian neoplasm
|
757 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.020 | 0.500 | 2 | 2016 | 2018 | |||||
Benign Prostatic Hyperplasia
|
91 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2004 | 2004 | |||||
Breast Cancer, Familial
|
91 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2005 | 2005 | |||||
cervical cancer
|
268 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2010 | 2010 | |||||
Cervix carcinoma
|
283 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2010 | 2010 | |||||
Childhood Osteosarcoma
|
151 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Congestive heart failure
|
165 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Fibroadenoma
|
1 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2008 | 2008 | |||||
Heart failure
|
201 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
HER2-negative breast cancer
|
18 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1 | 2014 | 2014 | ||||||
Invasive carcinoma of breast
|
21 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2005 | 2005 | |||||
Malignant neoplasm of gallbladder
|
81 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Malignant neoplasm of prostate
|
1082 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2004 | 2004 | |||||
Malignant neoplasm of thyroid
|
103 | 0.645 | 0.280 | 17 | 39723335 | missense variant | A/G;T | snv | 0.20 | 0.010 | 1.000 | 1 | 2009 | 2009 |